Toll-like receptor 4 (TLR4)-Myeloid differentiation factor 2 (MD-2) complex (TLR4-MD-2)

Toll-like receptor 4 (TLR4) in complex with its essential co-receptor Myeloid differentiation factor 2 (MD-2) serves as the primary sensor for lipopolysaccharide (LPS), a major component of Gram-negative bacterial cell walls (1.4.1, 1.4.2). This complex is a critical component of the innate immune system, triggering signaling cascades through MyD88-dependent and TRIF-dependent pathways that lead to the production of pro-inflammatory cytokines and type I interferons (1.2.3, 1.3.4). While essential for host defense against infections, dysregulated or excessive activation of the TLR4-MD-2 complex is implicated in the pathogenesis of sepsis, chronic inflammatory conditions, and certain cancers (1.2.1, 1.2.4). Therapeutic strategies include the development of antagonists like Eritoran and Resatorvid to treat inflammatory diseases, as well as agonists like GSK1795091 to enhance anti-tumor immunity (1.1.2, 1.3.1). The complex's role as a gatekeeper of inflammation makes it a high-value target for modulating immune responses across a broad spectrum of clinical indications (1.3.3). MD-2 is required for the cell surface expression of TLR4 and for the recognition of its ligands, making the physical interaction between these two proteins a focal point for drug discovery (1.4.3, 1.4.5).

Other names

TLR4-MD2 complexCD284-LY96 complexToll-like receptor 4-Lymphocyte antigen 96 complexLipopolysaccharide receptor complexhToll-MD2

Antagonism of the MD-2 binding pocket to prevent LPS-induced dimerization and signaling; inhibition of the TLR4 TIR domain to block adaptor recruitment; agonism to stimulate anti-tumor immune responses.